|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.16 USD | -2.83% |
|
-4.23% | +3.02% |
| 13/01 | Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln | RE |
| 13/01 | Sector Update: Health Care Stocks Lower in Afternoon Trading | MT |
Evolution of the Average Target: Sarepta Therapeutics, Inc.
Evolution of the Target Price: Sarepta Therapeutics, Inc.
Changes in Analyst Recommendations: Sarepta Therapeutics, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | -9.04% | |||||
| +169.84% | |||||
| Average | +80.40% | |||||
| Weighted average by Cap. | +79.05% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| RBC Capital Markets | |
| Mizuho Securities | |
| BofA Securities | |
| BMO Capital | |
| Deutsche Bank Securities | |
| Barclays | |
| Oppenheimer | |
| JPMorgan Chase | |
| Morgan Stanley | |
| Leerink Partners | |
| Baird | |
| Needham & Co. | |
| UBS | |
| William Blair & Co. | |
| TD Cowen | |
| Goldman Sachs | |
| Wolfe Research | |
| Jefferies & Co. | |
| Cantor Fitzgerald | |
| HC Wainwright | |
| Piper Sandler | |
| Scotiabank | |
| Wells Fargo Securities | |
| Wedbush | |
| Citigroup | |
| Evercore ISI | |
| Credit Suisse | |
| Berenberg Bank | |
| BTIG | |
| SVB Securities LLC | |
| Guggenheim |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SRPT Stock
- Consensus Sarepta Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition